The PCSK9 trials have confirmed (a) the absence of a J-point curve for LDL-C lowering and (b) continuing CV risk reduction, even when lowering LDL-C from 100 mg/dL to 30 mg/dL. In light of this how should the lipid specialist deploy PCSK9 inhibitors?

The PCSK9 trials have confirmed (a) the absence of a J-point curve for LDL-C lowering and (b) continuing CV risk reduction, even when lowering LDL-C from 100 mg/dL to 30 mg/dL. In light of this how should the lipid specialist deploy PCSK9 inhibitors?

CLICK HERE FOR CME CREDIT

The PCSK9 trials have confirmed (a) the absence of a J-point curve for LDL-C lowering and (b) continuing CV risk reduction, even when lowering LDL-C from 100 mg/dL to 30 mg/dL. In light of this how should the lipid specialist deploy PCSK9 inhibitors?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Michael H. Davidson, MD, FACC, FACP, FNLA

Michael H. Davidson, MD, FACC, FACP, FNLA

Clinical Professor

Clinical Professor
Director of Preventive Cardiology
The University of Chicago Hospitals and Clinic
Pritzker School of Medicine
Chicago, Illinois